Sign in to continue:

Monday, March 30th, 2026

Greenpro Capital Corp. 2025 Annual Report: Business Overview, Risk Factors, and Financial Highlights

Key Highlights from Greenpro Capital Corp.’s 2025 Annual Report (Form 10-K)

Greenpro Capital Corp. Releases 2025 Annual Report: Key Highlights and Potential Shareholder Impacts

Greenpro Capital Corp. (NASDAQ: GRNQ) has filed its Annual Report on Form 10-K for the fiscal year ended December 31, 2025. This comprehensive SEC filing provides critical insights into the company’s financial position, risk factors, and business strategy, all of which are of significant importance to investors and could potentially impact the company’s share price.

Key Points from the Annual Report

  • GRNQ remains listed on NASDAQ Capital Market under the trading symbol GRNQ. The company’s common stock, with a par value of \$0.0001, continues to be the only class of securities registered under Section 12(b) of the Securities Exchange Act.
  • As of March 30, 2026, there were 8,625,813 shares of Common Stock outstanding. This is a crucial metric for evaluating the company’s market capitalization and the dilution of existing shareholders.
  • Public Float: The aggregate market value of voting and non-voting common equity held by non-affiliates as of June 30, 2025, was \$7,592,303, based on the last reported sale price of \$1.57 per share. This figure is important as it reflects the liquidity and trading interest in the company’s shares.
  • Filing Status: Greenpro is a non-accelerated filer, a smaller reporting company, and is not an emerging growth company. These designations impact the regulatory burden and disclosure requirements for the company.
  • The company confirms it is not a shell company, affirming its ongoing business operations.
  • Greenpro has met all SEC reporting requirements during the past 12 months, and all interactive data files have been submitted as required. The company did not need to restate prior financial statements for error corrections or incentive-based compensation clawbacks.
  • Internal Controls: There is no attestation to management’s assessment of internal control over financial reporting by the company’s independent registered public accounting firm, as permitted for smaller reporting companies.

Forward-Looking Statements and Risks

The report contains a cautionary note regarding forward-looking statements. Shareholders should note the company’s outlook is subject to various risks, including but not limited to:

  • The availability and adequacy of cash flow to meet requirements
  • Economic, competitive, demographic, business, and other conditions in key markets
  • Changes in laws, regulations, or taxation affecting the industry
  • Actions by third parties, including suppliers, competitors, and government authorities
  • Industry competition
  • Changes in business strategy, capital improvements, or development plans
  • The availability of additional capital for improvements and development
  • Other risks identified in this and prior SEC filings

These factors could materially impact the company’s future performance and, consequently, the share price.

Matters Potentially Affecting Share Value

  • Share Count and Public Float: The relatively low public float and total shares outstanding make the stock vulnerable to volatility, which can lead to sharp price movements on news, trading, or changes in investor sentiment.
  • Regulatory Status: The company’s compliance with SEC reporting and non-shell status are positive signals for investors, indicating operational continuity and transparency.
  • Internal Controls: The absence of auditor attestation on internal controls is typical for smaller companies, but investors should remain vigilant for any future disclosures regarding the company’s control environment.
  • Forward-Looking Risks: The company’s exposure to economic, regulatory, and competitive risks should be monitored, as any adverse developments in these areas could significantly impact financial performance and share price.

Business Overview and Strategic Focus

Greenpro Capital Corp. is incorporated in Nevada and headquartered in Kuala Lumpur, Malaysia. It operates within the management consulting services industry, with a focus on providing a range of business advisory, corporate, and digital platform services. The company’s business segments and strategic priorities can influence future growth and profitability, which are essential considerations for investors.

Corporate Governance and Shareholder Communication

  • Greenpro provides disclosures on directors, executive officers, executive compensation, security ownership, related transactions, and principal accounting fees—all critical information for evaluating governance and management alignment with shareholder interests.
  • The company’s annual report includes a comprehensive index for ease of reference, covering business operations, risk factors, legal proceedings, MD&A, and financial statements.

Conclusion

The 2025 Form 10-K filing by Greenpro Capital Corp. offers valuable transparency into the company’s operations, risks, and compliance status. The most price-sensitive factors include the low public float, share count, compliance with SEC regulations, and the array of risks in the competitive landscape. Investors should continue monitoring regulatory filings, market developments, and the company’s execution on its business strategy for any changes that could impact share value.


Disclaimer: This summary is for informational purposes only and does not constitute investment advice. Investors should read the full Form 10-K and consult with their financial advisors before making investment decisions. All forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially.


View Greenpro Capital Corp. Historical chart here



iRhythm Holdings Appoints Jason Patten to Board of Directors – March 2026 Announcement 6

iRhythm Holdings Appoints Jason Patten to Board of Directors...

Curanex Pharmaceuticals Executive Employment Agreements and Proprietary Information Assignment – SEC Filing Details

Curanex Pharmaceuticals Inc. Form 8-K Detailed Investor Repo...

Werewolf Therapeutics Explores Strategic Alternatives Including Sale, Merger, or Partnerships to Maximize Stockholder Value

Werewolf Therapeutics Initiates Review of Strategic Alternat...

   Ad